Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
FibromyalgiaSleepChronic Pain
Interventions
DRUG

eplivanserin (SR46349)

oral administration

DRUG

placebo

oral administration

Trial Locations (12)

30328

Comprehensive Neuroscience, Atlanta

32216

Jacksonville Center for Clinical Research, Jacksonville

33173

Miami Research Assoc., Inc., Miami

34471

Renstar Medical Research, Ocala

46250

Physicians Research Group, Indianapolis

67208

Wichita Clinic PA, Wichita

68114

Westroads Medical Group, Omaha

84403

Physicians Research Options, Ogden

85013

Radiant Research, Phoenix

92108

San Diego Arthritis Medical Clinic, San Diego

98104

Seattle Rheumatology Assoc., Seattle

Unknown

Sanofi-Aventis Administrative Office, Laval

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00313885 - Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia | Biotech Hunter | Biotech Hunter